Inhibikase Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | $0 | $260,501 | $123,440 | $3.1M |
| Selling, general & administrative | $23.6M | $11.4M | $6.7M | $6.2M | $6.5M |
| Research and development | $29.8M | $17.2M | $13.6M | $12.0M | $11.4M |
| Operating income | -$52.0M | -$28.6M | -$20.1M | -$18.1M | -$14.8M |
| Interest expense | — | — | — | — | $19,923 |
| Pretax income | -$48,259 | -$27,520 | — | — | — |
| Income tax expense | $0 | $0 | — | — | — |
| Net income | -$48.3M | -$27.5M | -$19.0M | -$18.1M | -$14.8M |
| Balance Sheet | |||||
| Cash and equivalents | $178.8M | $97.5M | $9.2M | $7.2M | $40.8M |
| Current assets | $180.1M | $98.5M | $14.2M | $24.4M | $42.5M |
| Total assets | $181.2M | $98.6M | $14.5M | $24.9M | $42.5M |
| Current liabilities | $8.3M | $3.7M | $3.4M | $3.7M | $4.1M |
| Total liabilities | $8.3M | $3.7M | $3.5M | $3.9M | $4.1M |
| Stockholders' equity | $172.9M | $94.9M | $11.0M | $21.0M | $38.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$27.8M | -$19.1M | -$18.1M | -$17.4M | -$14.3M |
| Depreciation and amortization | $60,499 | $26,272 | $177,398 | $6,723 | $0 |
| Stock-based compensation | $15.3M | $8.1M | $500,148 | $458,147 | $1.5M |
| Capital expenditure | $13,399 | $0 | $14,238 | $243,255 | $0 |
| Free cash flow | -$27.8M | -$19.1M | -$18.1M | -$17.6M | -$14.3M |
Shares outstanding 132.0M · Free float 71.6%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.